Markedly diminished lapolysis and partial restoration of glucose metabolism, without changes in fat distribution after extended discontinuation of protease inhibitors in severe lipodystrophic human immunodeficient virus-1-infected patients

Journal of Clinical Endocrinology and Metabolism

Volumn 89, Issue 7, 2004, Pages 3554-3560

  Van Der Valk, Marc ^a,c   Allick, Gideon ^a   Weverling, Gerrit Jan ^a   Romijn, Johannes A ^b   Ackermans, Mariette T ^a   Lange, Joep M A ^a   Van Eck Smit, Berthe L F ^a   Van Kuijk, Cornelis ^a   Endert, Erik ^a   Sauerwein, Hans P ^a   Reiss, Peter ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; FAT; GLUCOSE; INSULIN; LIPID; PROTEINASE INHIBITOR; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; GLYCEROL;

ADULT; ARTICLE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERINSULINEMIA; LIPID COMPOSITION; LIPODYSTROPHY; LIPOLYSIS; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; ADIPOSE TISSUE; BODY COMPOSITION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG EFFECT; GLUCOSE CLAMP TECHNIQUE; HIV ASSOCIATED LIPODYSTROPHY; HOSPITALIZATION; INSULIN RESISTANCE; MALE; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; RADIODENSITOMETRY; RADIOGRAPHY; RANDOMIZED CONTROLLED TRIAL; RETREATMENT;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

ADIPOSE TISSUE; ADULT; ANTI-HIV AGENTS; BODY COMPOSITION; DENSITOMETRY, X-RAY; DIDEOXYNUCLEOSIDES; DRUG ADMINISTRATION SCHEDULE; GLUCOSE; GLUCOSE CLAMP TECHNIQUE; GLYCEROL; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; INSULIN RESISTANCE; LIPOLYSIS; MALE; MIDDLE AGED; PROTEASE INHIBITORS; RETREATMENT; SEVERITY OF ILLNESS INDEX; TOMOGRAPHY, X-RAY COMPUTED;

EID: 3242740785     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2003-030985     Document Type: Article

References (34)

1. Carr A, Samaras K, Burton S, Law MG, Freund J, Chrisholm DJ, Cooper D 1998 A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 12:F51-F58
2. Carr A, Miller J, Law M, Cooper DA 2000 A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS 14:F25-F32
3. van der Valk M, Gisolf EH, Reiss P, Wit FWNM, Japour AJ, Weverling GJ, Danner SA 2000 Increased risk of lipodystrophy when including NRTI's in the treatment of HIV-1 infection with PI's: results from a randomized controlled trial. AIDS 15:847-855
4. Martinez E, Mocroft A, Garcia-Viejo MA, Perez-Cuevas JB, Blanco JL, Mallolas J, Bianchi L, Conget I, Blanch J, Phillips A, Gatell JM 2001 Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. Lancet 357:592-598
5. Schambelan M, Benson CA, Carr A, Currier JS, Dube MP, Gerber JG, Grinspoon SK, Granfeld C, Kotler DP, Mulligan K, Powderly WG, Saag MS 2002 Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel. J Acquir Immune Defic Syndr 31:257-275
6. Mallal S, John M, Moore C, James I, McKinnon EJM 2000 Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS 14:1309-1316
7. Saint-Marc T, Partisani M, Poizot-Martin I, Bruno F, Rouviere O, Lang JM, Gastaut JA, Touraine JL 1999 A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS 13:1659-1667
8. Heath KV, Hogg RS, Chan KJ, Harris M, Montessori V, O'Shaughnessy MV, Montanera JS 2001 Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment database. AIDS 15:231-239
9. Gervasoni C, Ridolfo AL, Trifiro G, Santambrogio S, Norbiato G, Musicco M, Clerici M, Galli M, Moroni M 1999 Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy. AIDS 13:465-471
10. Reitman ML, Arioglu E, Gavrilova O, Taylor SI 2000 Lipoatrophy revisited. Trends Endocrinol Metab 11:410-416
11. Gavrilova O, Marcus-Samuels B, Graham D, Kim JK, Shulman GI, Castle AL, Vinson C, Eckhaus M, Reitman ML 2000 Surgical implantation of adipose tissue reverses diabetes in lipoatrophic mice. J Clin Invest 105:271-278
12. van der Valk M, Bisschop PH, Romijn JA, Ackermans MT, Lange JM, Endert E, Reiss P, Sauerwein HP 2001 Lipodystrophy in HIV-1 positive subjects is associated with insulin resistance in multiple metabolic pathways. AIDS 15:2093-2100
13. Behrens GM, Boerner AR, Weber K, van den HJ, Ockenga J, Brabant G, Schmidt RE 2002 Impaired glucose phosphorylation and transport in skeletal muscle cause insulin resistance in HIV-1-infected patients with lipodystrophy. J Clin Invest 110:1319-1327
14. van der Valk M, Reiss P, van Leth FC, Ackermans MT, Endert E, Romijn JA, Heijligenberg R, Sauerwein H 2002 Highly active antiretrovirat therapy-induced lipodystrophy has minor effects on human immunodeficiency virus-induced changes in lipolysis, but normalizes resting energy expenditure. J Clin Endocrinol Metab 87:5066-5071
15. Heijligenberg R, Romijn JA, Klein S, Endert E, Sauerwein HP 1997 Lipolytic sensitivity to catecholamines in patients with human immunodeficiency virus infection. Am J Clin Nutr 66:633-638
16. Hommes MJ, Romijn JA, Endert E, Eeftinck SJ, Sauerwein HP 1991 Insulin sensitivity and insulin clearance in human immunodeficiency virus-infected men. Metabolism 40:651-656
17. Noor MA, Seneviratne T, Aweeka FT, Lo JC, Schwarz JM, Mulligan K, Schambelan M, Grunfeld C 2002 Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study. AIDS 16:F1-F8
18. Purnell JQ, Zambon A, Knopp RH, Pizzuti DJ, Achari R, Leonard JM, Locke C, Branzell JD 2000 Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects. AIDS 14:51-57
19. Murata H, Hruz PW, Mueckler M 2002 Indinavir inhibits the glucose transporter isoform Glut4 at physiologic concentrations. AIDS 16:859-863
20. Murata H, Hraz PW, Mueckler M 2000 The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J Biol Chem 275:20251-20254
21. Walli RK, Michl GM, Bogner JR, Goebel FD 2001 Improvement of HAART-associated insulin resistance and dyslipidemia after replacement of protease inhibitors with abacavir. Eur J Med Res 6:413-421
22. Martinez E, Garcia-Viejo MA, Blanco JL, Bianchi L, Buira E, Conget I, Casamitjana R, Mallolas J, Gatell JM 2000 Impact of switching from human immunodeficiency virus type 1 protease inhibitors to efavirenz in successfully treated adults with lipodystrophy. Clin Infect Dis 31:1266-1273
23. Carr A, Hudson J, Chuah J, Mallal S, Law M, Hoy J, Doong N, French M, Smith D, Cooper DA 2001 HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study. AIDS 15:1811-1822
24. Hadigan C, Borgonha S, Rabe J, Young V, Grinspoon S 2002 Increased rates of lipolysis among human immunodeficiency virus-infected men receiving highly active antiretroviral therapy. Metabolism 51:1143-1147
25. 1997 Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 20:1183-1197
26. Molina JM, Baron AD, Edelman SV, Brechtel G, Wallace P, Olefsky JM 1990 Use of a variable tracer infusion method to determine glucose turnover in humans. Am J Physiol 258:E16-E23
27. Levy JC, Brown G, Matthews DR, Turner RC 1989 Hepatic glucose output in humans measured with labeled glucose to reduce negative errors. Am J Physiol 257:E531-E540
28. Frayn KN 1983 Calculation of substrate oxidation rates in vivo from gaseous exchange. J Appl Physiol 55:628-634
29. Hommes MJ, Romijn JA, Endert E, Eeftinck SJ, Sauerwein HP 1991 Basal fuel homoeostasis in symptomatic human immunodeficiency virus infection. Clin Sci (Colch) 80:359-365
30. Noor MA, Lo JC, Mulligan K, Schwarz JM, Halvorsen RA, Schambelan M, Grunfeld C 2001 Metabolic effects of indinavir in healthy HIV-seronegative men. AIDS 15:F11-F18
31. Renard E, Fahre J, Paris F, Reynes J, Bringer J 1999 Syndrome of body fat redistribution in HIV-1-infected patients: relationships to cortisol and catecholamines. Clin Endocrinol (Oxf) 51:223-230
32. Ferrannini E, Vichi S, Beck-Nielsen H, Laakso M, Paolisso G, Smith U 1996 Insulin action and age. European Group for the Study of Insulin Resistance (EGIR). Diabetes 45:947-953
33. Gumbiner B, Thorburn AW, Ditzler TM, Bulacan F, Henry RR 1992 Role of impaired intracellular glucose metabolism in the insulin resistance of aging. Metabolism 41:1115-1121
34. Opravil M, Hirschel B, Lazzarin A, Furrer H, Chave JP, Yerly S, Bisset LR, Fischer M, Vernazza P, Bernasconi E, Battegay M, Ledergerber B, Gunthard H, Howe C, Weber R, Perrin L 2002 A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection. J Infect Dis 185:1251-1260